AngioDynamics, Inc.
NASDAQ Global SelectTotal Valuation
AngioDynamics, Inc. carries a market capitalization of 566.67M, placing it among publicly traded companies globally. Its enterprise value stands at 422.58M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 566.67M |
| Enterprise Value | 422.58M |
Share Statistics
AngioDynamics, Inc. currently has 41.70M shares outstanding.
| Shares Outstanding | 41.70M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 1.49, and the price-to-book ratio stands at -1.02.
| PE Ratio | N/A |
| PS Ratio | 1.49 |
| PB Ratio | -1.02 |
| P/TBV Ratio | 4.60 |
| P/FCF Ratio | 84.03 |
| P/OCF Ratio | 154.24 |
Enterprise Valuation
On an enterprise value basis, AngioDynamics, Inc. trades at an EV/EBITDA multiple of 675.05 and an EV/FCF ratio of 74.53.
| EV / Sales | 1.32 |
| EV / EBITDA | 675.05 |
| EV / EBIT | N/A |
| EV / FCF | 74.53 |
Financial Position
AngioDynamics, Inc. maintains a current ratio of 2.19, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.19 |
| Quick Ratio | 1.37 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -13.43 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.54 |
Taxes
| Income Tax | 442,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
AngioDynamics, Inc.'s stock has gained approximately 52.50278% over the past 52 weeks. The 50-day moving average sits at 12.17, while the 200-day moving average is 11.63.
| Beta (5Y) | N/A |
| 52-Week Price Change | 52.50278% |
| 50-Day Moving Average | 12.17 |
| 200-Day Moving Average | 11.63 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, AngioDynamics, Inc. generated 320.17M in revenue and converted that into -36.74M in net income, yielding earnings per share of -0.89. EBITDA reached 626,000.00, while operating income came in at -22.33M.
| Revenue | 320.17M |
| Gross Profit | 174.89M |
| Operating Income | -22.33M |
| Pretax Income | -36.30M |
| Net Income | -36.74M |
| EBITDA | 626,000.00 |
| EBIT | -22.33M |
| Earnings Per Share (EPS) | -0.89 |
Balance Sheet
Total book value stands at -465.55M, with working capital of 88.68M providing operational flexibility.
| Cash & Cash Equivalents | 53.86M |
| Total Debt | N/A |
| Net Debt | -53.86M |
| Equity (Book Value) | -465.55M |
| Book Value Per Share | -11.22 |
| Working Capital | 88.68M |
Cash Flow
AngioDynamics, Inc. produced 3.09M in operating cash flow over the past twelve months. After subtracting -2.58M in capital expenditures, free cash flow totaled 508,000.00 - equivalent to 0.01 per share.
| Operating Cash Flow | 3.09M |
| Capital Expenditures | -2.58M |
| Free Cash Flow | 508,000.00 |
| FCF Per Share | 0.01 |
Margins
AngioDynamics, Inc. operates with a gross margin of 54.62, reflecting its pricing power and cost economics. The operating margin of -6.97 and net profit margin of -11.48 provide insight into operational efficiency.
| Gross Margin | 54.62 |
| Operating Margin | -6.97 |
| Pretax Margin | -11.34 |
| Profit Margin | -11.48 |
| EBITDA Margin | 0.20 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.12 |
| FCF Yield | 1.19 |
Scores
AngioDynamics, Inc. posts an Altman Z-Score of 1.47, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.47 |